• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    JTC Team Announces Presenting Company Line-Up for the Virtual Investor Summer Spotlight Series

    7/6/23 12:00:00 PM ET
    $AEZS
    $AREC
    $ATOS
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Coal Mining
    Energy
    Get the next $AEZS alert in real time by email

    - Event taking place on July 11th, 12th, and 13th -

    - Live video webcast with moderated interactive discussion with participating companies -

    - Access the event at www.virtualinvestorco.com -

    FRENCHTOWN, NJ / ACCESSWIRE / July 6, 2023 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced the presenting company line-up for its Virtual Investor Summer Spotlight Series being held on July 11-13, 2023. The virtual event will include a moderated roundtable discussion or company presentation and an interactive Q&A session allowing for questions from the conference attendees.

    The schedule for the event is as follows:

    Tuesday, July 11, 2023

    • 11:00 AM ET: iTolerance, Inc. - WEBCAST
    • 12:00 PM ET: CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) - WEBCAST
    • 1:00 PM ET: Exxel Pharma - WEBCAST
    • 2:00 PM ET: GRI Bio, Inc. (NASDAQ:GRI) - WEBCAST
    • 3:00 PM ET: Morphogenesis, Inc. - WEBCAST
    • 4:00 PM ET: Adolore Biotherapeutics, Inc. - WEBCAST

    Wednesday, July 12, 2023

    • 10:00 AM ET: Xenetic Biosciences, Inc. (NASDAQ:XBIO) - WEBCAST
    • 11:00 AM ET: AIM Immunotech, Inc. (NYSE:AIM) - WEBCAST
    • 12:00 PM ET: Ceapro, Inc. (TSXV:CZO, OTCQX:CRPOF) - WEBCAST
    • 2:00 PM ET: American Resources Corporation (NASDAQ:AREC) - WEBCAST
    • 3:00 PM ET: Moleculin Biotech, Inc. (NASDAQ:MBRX) - WEBCAST
    • 4:00 PM ET: Evofem Biosciences, Inc. (OTCQB:EVFM) - WEBCAST

    Thursday, July 13, 2023

    • 10:00 AM ET: Aeterna Zentaris, Inc. (NASDAQ:AEZS, TSX:AEZS) - WEBCAST
    • 11:00 AM ET: Atossa Therapeutics, Inc. (NASDAQ:ATOS) - WEBCAST
    • 12:00 PM ET: enVVeno Medical Corporation (NASDAQ:NVNO) - WEBCAST
    • 2:00 PM ET: Panavance Therapeutics, Inc. - WEBCAST

    About JTC Team

    JTC is a fully integrated corporate communications firm that is dedicated to helping you tell your story to the right audiences in order to build awareness. JTC has developed a reputation of excellence for executing robust communication strategies that deliver results. The Company partners with both public and private companies across the Life Sciences and Technology industries to help raise awareness and build stakeholder value. For more information, please visit www.jtcir.com or connect with the company on Twitter and LinkedIn.

    Contact:

    Jenene Thomas
    JTC Team, LLC
    T: +1 (833) 475-8247
    [email protected]

    SOURCE: JTC Team, LLC



    View source version on accesswire.com:
    https://www.accesswire.com/765989/JTC-Team-Announces-Presenting-Company-Line-Up-for-the-Virtual-Investor-Summer-Spotlight-Series

    Get the next $AEZS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEZS
    $AREC
    $ATOS
    $CNSP

    CompanyDatePrice TargetRatingAnalyst
    American Resources Corporation
    $AREC
    11/26/2025$7.00Buy
    Maxim Group
    American Resources Corporation
    $AREC
    10/20/2025Outperform
    William Blair
    American Resources Corporation
    $AREC
    9/15/2025$6.00Buy
    D. Boral Capital
    Moleculin Biotech Inc.
    $MBRX
    6/9/2025$4.00Buy
    H.C. Wainwright
    Moleculin Biotech Inc.
    $MBRX
    2/12/2025Buy → Hold
    Maxim Group
    GRI Bio Inc.
    $GRI
    12/9/2024$10.00Buy
    H.C. Wainwright
    Moleculin Biotech Inc.
    $MBRX
    7/18/2022$14.00Outperform
    Oppenheimer
    Evofem Biosciences Inc.
    $EVFM
    3/4/2022$0.50 → $0.53Underweight
    Morgan Stanley
    More analyst ratings

    $AEZS
    $AREC
    $ATOS
    $CNSP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Golden Properties Ltd. decreased direct ownership by 7% to 12,389,960 units (SEC Form 4)

    4 - American Resources Corp (0001590715) (Issuer)

    8/20/25 12:33:35 PM ET
    $AREC
    Coal Mining
    Energy

    Large owner Golden Properties Ltd. decreased direct ownership by 7% to 13,389,960 units (SEC Form 4)

    4 - American Resources Corp (0001590715) (Issuer)

    8/1/25 1:26:00 PM ET
    $AREC
    Coal Mining
    Energy

    Chief Financial Officer Foster Jonathan P. covered exercise/tax liability with 1,715 shares, bought $100,000 worth of shares (270,270 units at $0.37) and converted options into 7,039 shares, increasing direct ownership by 2,298% to 287,587 units (SEC Form 4)

    4 - Moleculin Biotech, Inc. (0001659617) (Issuer)

    6/23/25 4:35:31 PM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEZS
    $AREC
    $ATOS
    $CNSP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $AEZS
    $AREC
    $ATOS
    $CNSP
    SEC Filings

    View All

    $AEZS
    $AREC
    $ATOS
    $CNSP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Maxim Group initiated coverage on American Resources Corp. with a new price target

    Maxim Group initiated coverage of American Resources Corp. with a rating of Buy and set a new price target of $7.00

    11/26/25 7:50:43 AM ET
    $AREC
    Coal Mining
    Energy

    William Blair initiated coverage on American Resources Corp.

    William Blair initiated coverage of American Resources Corp. with a rating of Outperform

    10/20/25 8:43:21 AM ET
    $AREC
    Coal Mining
    Energy

    D. Boral Capital resumed coverage on American Resources Corp. with a new price target

    D. Boral Capital resumed coverage of American Resources Corp. with a rating of Buy and set a new price target of $6.00

    9/15/25 8:07:21 AM ET
    $AREC
    Coal Mining
    Energy

    SEC Form 10-K filed by CNS Pharmaceuticals Inc.

    10-K - CNS Pharmaceuticals, Inc. (0001729427) (Filer)

    3/31/26 4:30:28 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form NT 10-K filed by American Resources Corporation

    NT 10-K - American Resources Corp (0001590715) (Filer)

    3/31/26 4:30:05 PM ET
    $AREC
    Coal Mining
    Energy

    SEC Form DEF 14A filed by Atossa Therapeutics Inc.

    DEF 14A - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)

    3/30/26 5:30:46 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update

    SEATTLE, March 25, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announces its financial results for the fourth quarter and year ended December 31, 2025 and provides an update on recent corporate developments. "While we have consistently made meaningful and measurable progress across our (Z)-endoxifen development strategy in oncology over the last 12 months, we continue to explore the best opportunities to le

    3/25/26 5:30:00 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout

    First Interim Unblinding of Pivotal AML Trial Now Imminent — Potentially the Most Important Data Moment in Company HistoryEarly Blinded Results Show 40% Remission Rate Across Difficult-to-Treat Patient PopulationEnrollment Accelerating Toward 90 Subject Threshold as Phase 3 Pathway Takes Shape HOUSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announced that the 45th subject has been enrolled in its pivotal Phase 2B/3 MIRACLE trial evaluating Annamycin in combination with cytarabine (AnnAraC) for the treatment of adult subjects with relapsed or refractory acute myeloid leukemia (R/R AML). This milestone triggers the fin

    3/23/26 8:31:00 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The $30B Catalyst Reshaping America's Mineral Supply

    VANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary — The Department of Energy just launched a pivotal $500 million initiative to fund domestic mineral processing. It is a massive structural shift showing that America is finally moving to fix the midstream bottlenecks that leave US manufacturers exposed to foreign supply shocks[1]. Concurrently, the 2026 Critical Minerals Ministerial mobilized more than $30 billion in government-backed capital to accelerate local project development and streamline regulatory hurdles[2]. This wave of scalable investment is rapidly repricing undervalued onshore assets. Positioned directly in the path of this dom

    3/19/26 11:00:00 AM ET
    $AREC
    $NB
    $RYZ
    Coal Mining
    Energy
    Metal Mining
    Basic Materials

    $AEZS
    $AREC
    $ATOS
    $CNSP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Quay Steven C

    4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)

    3/31/26 4:57:01 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Daniel Mark James

    4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)

    3/30/26 7:22:50 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO & President Equels Thomas K converted options into 25,000 shares, increasing direct ownership by 64% to 63,922 units (SEC Form 4)

    4 - AIM ImmunoTech Inc. (0000946644) (Issuer)

    3/16/26 5:30:41 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AEZS
    $AREC
    $ATOS
    $CNSP
    Financials

    Live finance-specific insights

    View All

    Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026

    Miracle Trial Preliminary Blinded CRc Rate of 40% in First 30 Patients Suggests Encouraging Early Results in Relapsed/Refractory AML HOUSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today reported financial results for the year ended December 31, 2025 and provided a clinical update highlighting rapid progress toward a major upcoming milestone in its pivotal MIRACLE trial of Annamycin in combination with cytarabine for the treatment of adult patients with acute myeloid leukemia (AML) who are refractory to or relapsed (R/R) after induction therapy (R/R AML). "With the MIRACLE trial rapidly progressing and the first MIRACLE i

    3/19/26 8:36:00 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AIM ImmunoTech Announces Stock Dividend

    OCALA, Fla., Dec. 30, 2025 (GLOBE NEWSWIRE) --  AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced a stock dividend of one share of common stock for every 1,000 shares of outstanding common stock as well as one share of common stock for every outstanding option or warrant that has a right to receive stock dividends ("Alternate Securities"). The dividend will be issuable to stockholders and Alternate Securities holders of record at the close of business on January 9, 2026 and will be distributed and allocated to DTCC on January 13, 2026. Resulting fractional shares will be rounded down and any resulting fractional shares remaining after the foregoing rounding down will

    12/30/25 5:10:00 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update

    -- Increased Net Sales 10% While Lowering Operating Expenses 42% vs. Prior Year Quarter -- -- Delivered $1.0 Million of Operating Income in Q3 2025 -- SAN DIEGO, Nov. 13, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (Evofem or the Company) (OTCID: EVFM), today announced financial results for the three- and nine-month periods ended September 30, 2025 and provided a business update. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> "Sales rebounded in the thi

    11/13/25 4:05:00 PM ET
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEZS
    $AREC
    $ATOS
    $CNSP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by AIM ImmunoTech Inc.

    SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)

    12/17/24 4:11:23 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Moleculin Biotech Inc.

    SC 13G/A - Moleculin Biotech, Inc. (0001659617) (Subject)

    11/14/24 5:12:06 PM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by enVVeno Medical Corporation

    SC 13G/A - enVVeno Medical Corp (0001661053) (Subject)

    11/14/24 4:50:32 PM ET
    $NVNO
    Medical/Dental Instruments
    Health Care

    $AEZS
    $AREC
    $ATOS
    $CNSP
    Leadership Updates

    Live Leadership Updates

    View All

    Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives

    Kathy Puyana Theall, M.D. and Adebola Giwa, M.D. bring deep expertise across oncology, rare diseases, and global clinical development to support advancement of Atossa's pipelineSEATTLE, March 19, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other rare diseases, today announces the engagement of Kathy Puyana Theall, M.D., as Medical Director - Breast Oncology, and Adebola Giwa, M.D., as Medical Director - Rare Diseases.  The addition of these two highly experienced physicians and clinical leaders meaningfully strengthens Atossa's ability to execute on its (Z)-endo

    3/19/26 8:00:00 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook

    SEATTLE, Feb. 11, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet need, today issued a letter to Shareholders from Steven Quay, M.D., Ph.D., Atossa Therapeutics President and Chief Executive Officer, providing an update on the Company's clinical programs and recent events. The full text of the letter follows: To our valued shareholders, In looking back on 2025, Atossa made meaningful progress advancing proprietary oral (Z)-en

    2/11/26 8:30:00 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness

    25+ year life-sciences finance leader brings revenue-forecasting rigor, public-company controls, and capital-markets experience as Atossa prepares for commercial operations with (Z)-endoxifen SEATTLE, Oct. 14, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing new approaches in breast cancer treatment and prevention, announces the appointment of Mark Daniel, CPA (WA; inactive), as Chief Financial Officer. Mr. Daniel is a senior finance leader with more than 25 years of experience building the forecasting cadence, systems, and public-company discipline that support revenue scale in global life-science

    10/14/25 8:00:00 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care